Cisplatin-based chemotherapy is essential to treat many childhood cancers but causes irreversible hearing loss (HL). This study examines hearing-related quality of life (HR-QOL) in cisplatin-treated pediatric cancer survivors.
✦ The floor
Discussion
Signed responses from readers of the wire.
Audiologists working with pediatric oncology patients should prioritize hearing monitoring during and after cisplatin treatment and proactively address rehabilitation needs, as irreversible hearing loss demonstrably impairs survivors' quality of life.
With childhood cancer survival rates improving, the long-term burden of cisplatin-induced hearing loss (ototoxicity) on quality of life is an increasingly critical survivorship issue that demands attention from both oncology and audiology teams.
- 01Cisplatin-induced ototoxicity (drug-related hearing damage) causes irreversible hearing loss in childhood cancer survivors.
- 02Study links cisplatin hearing loss directly to measurable reductions in hearing-related quality of life.
- 03Published in JCO Oncology Practice, signaling relevance to oncology-audiology collaborative care.
- 04Findings support the clinical case for routine ototoxicity monitoring during pediatric chemotherapy.
- 05Results may inform shared decision-making conversations with families about cisplatin treatment risks.
Cisplatin-induced hearing loss significantly reduces hearing-related quality of life in childhood cancer survivors.
studysupportedHearing loss caused by cisplatin in childhood cancer survivors is irreversible.
studysupported- PMID
- 42330418
- DOI
- 10.1200/OP-25-01414.
- Journal
- JCO Oncology Practice
- Publication type
- research_article
- Evidence level
- 2b
- Population
- Childhood cancer survivors who experienced irreversible hearing loss following cisplatin-based chemotherapy
- Intervention
- Cisplatin-induced hearing loss (ototoxicity)
Primary outcomes
Hearing-related quality of life scores in childhood cancer survivors